Novartis will pay $72 a share in cash for the biotechnology company, representing a premium of 46% to Avidity’s closing price ...

(Oct 27): Novartis AG agreed to buy biotechnology company Avidity Biosciences Inc in a deal valued at US$12 billion, making ...

Biogen will pay a Chicago biotech $70 million upfront, plus up to $990 million in milestone payments, for an early-stage ...

Sen. Bill Cassidy, MD (R-La.), chair of the committee, applauded medical innovations of the last few decades including ...

Ipsen is set to purchase all issued and outstanding shares of the French biotech company ImCheck Therapeutics.

Nanobiotix is continuing to find fresh ways to eke money out of its Johnson & Johnson-partnered, phase 3-stage cancer drug. | ...

NEW YORK] Novartis agreed to buy biotechnology company Avidity Biosciences in a deal that values it at US$12 billion, ...

Federal regulators are trying to make it easier to develop cheaper alternatives to powerful drugs that many Americans depend ...

The biotechnology giant’s board will front angry investors this week after losing more than a quarter of its market value ...

Some companies are pitching a new model for employers to help their workers pay for medications, but without using insurance.

Alexandria Real Estate Equities, Inc. faces ongoing headwinds, with soft biotech demand, and declining occupancy. Learn more ...

Fresh from a European cancer conference that was all about antibody-drug conjugates (ADCs), GSK has turned to French biotech ...